Shattuck Labs Inc. (STTK): Price and Financial Metrics

Shattuck Labs Inc. (STTK): $1.51

0.02 (-1.31%)

POWR Rating

Component Grades








Add STTK to Watchlist
Sign Up

Industry: Biotech




#271 of 383

in industry

STTK Price/Volume Stats

Current price $1.51 52-week high $4.77
Prev. close $1.53 52-week low $1.51
Day low $1.51 Volume 293,500
Day high $2.11 Avg. volume 32,195
50-day MA $2.27 Dividend yield N/A
200-day MA $2.89 Market Cap 64.13M

STTK Stock Price Chart Interactive Chart >


  • STTK scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.7% of US stocks.
  • The strongest trend for STTK is in Quality, which has been heading down over the past 34 days.
  • STTK ranks lowest in Momentum; there it ranks in the 6th percentile.

STTK Stock Summary

  • Of note is the ratio of SHATTUCK LABS INC's sales and general administrative expense to its total operating expenses; merely 8.49% of US stocks have a lower such ratio.
  • STTK's price/sales ratio is 97.9; that's higher than the P/S ratio of 97.77% of US stocks.
  • As for revenue growth, note that STTK's revenue has grown -97.32% over the past 12 months; that beats the revenue growth of merely 0.91% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to SHATTUCK LABS INC, a group of peers worth examining would be SEEL, SPRB, PIRS, ABUS, and IKNA.
  • Visit STTK's SEC page to see the company's official filings. To visit the company's web site, go to

STTK Valuation Summary

  • STTK's price/sales ratio is 97.9; this is 5052.63% higher than that of the median Healthcare stock.
  • STTK's price/sales ratio has moved up 23.4 over the prior 36 months.

Below are key valuation metrics over time for STTK.

Stock Date P/S P/B P/E EV/EBIT
STTK 2023-09-18 97.9 0.6 -0.9 -0.2
STTK 2023-09-15 101.4 0.6 -0.9 -0.2
STTK 2023-09-14 103.4 0.6 -1.0 -0.2
STTK 2023-09-13 101.4 0.6 -0.9 -0.2
STTK 2023-09-12 103.8 0.6 -1.0 -0.2
STTK 2023-09-11 108.3 0.7 -1.0 -0.3

STTK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • STTK has a Quality Grade of C, ranking ahead of 29.15% of graded US stocks.
  • STTK's asset turnover comes in at 0.006 -- ranking 405th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows STTK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.006 1 -0.376
2020-12-31 0.050 1 -0.381

STTK Price Target

For more insight on analysts targets of STTK, see our STTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $48.00 Average Broker Recommendation 1.5 (Moderate Buy)

Shattuck Labs Inc. (STTK) Company Bio

Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals. Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients.

STTK Latest News Stream

Event/Time News Detail
Loading, please wait...

STTK Latest Social Stream

Loading social stream, please wait...

View Full STTK Social Stream

Latest STTK News From Around the Web

Below are the latest news stories about SHATTUCK LABS INC that investors may wish to consider to help them evaluate STTK as an investment opportunity.

Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates

Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 3.85% and 44.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 10, 2023

Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights

– Presented complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 annual meeting, including data supporting 3 mg/kg as the appropriate dose for each PROC combination cohort – – Completed enrollment in the dose-escalation portion of the Phase 1A/B clinical trial of SL-172154 in relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS); and

Yahoo | August 10, 2023

Companies Like Shattuck Labs (NASDAQ:STTK) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | July 6, 2023

Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose – AUSTIN, TX and DURHAM, NC, May 25, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune d

Yahoo | May 25, 2023

Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates

Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 19.67% and 83.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 9, 2023

Read More 'STTK' Stories Here

STTK Price Returns

1-mo -28.77%
3-mo -54.10%
6-mo -49.67%
1-year -44.07%
3-year N/A
5-year N/A
YTD -34.35%
2022 -72.97%
2021 -83.76%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!